Glutamate receptor ligands: Synthesis, stereochemistry, and enantiopharmacology of methylated 2‐aminoadipic acid analogs

Abstract

Homologation and substitution on the carbon backbone of (S)-glutamic acid [(S)-Glu, 1], as well as absolute stereochemistry, are structural parameters of key importance for the pharmacological profile of (S)-Glu receptor ligands. We describe a series of methyl-substituted 2-aminoadipic acid (AA) analogs, and the synthesis, stereochemistry, and enantiopharmacology of 3-methyl-AA (4a-d), 4-methyl-AA (5a-d), 5-methyl-AA (6a-d), and (E)-Delta(4)-5-methyl-AA (7a and 7b) are reported. The compounds were resolved using chiral HPLC and the configurational assignments of the enantiomers were based on X-ray crystallographic analyses, chemical correlation, and CD spectral analyses. The effects of the individual stereoisomers at ionotropic and metabotropic (S)-Glu receptors (iGluRs and mGluRs) were characterized. Compounds with S-configuration at the alpha-carbon generally showed mGluR2 agonist activity of similar or slightly lower potencies than (S)-AA [e.g., EC(50) = 76 microM for (2S,4S)-4-methyl-AA (5a) as compared to EC(50) = 35 microM for (S)-AA]. The position of the methyl substituent had a profound effect on the observed pharmacology, whereas the absolute stereochemistry at the methylated carbon atom had a very limited effect on pharmacology. Structure-activity relationships at iGluRs in the rat cortical wedge preparation showed a complex pattern, some compounds being NMDA receptor agonists [e.g., EC(50) =110 microM for (2S,5RS)-5-methyl-AA (6a,b)] and some compounds showing NMDA receptor antagonist effects [e.g., IC(50) = 300 microM for (2R,4S)-4-methyl-AA (5d)]. The two unsaturated analogs (S)- (7a) and (R)-(E)-Delta(4)-5-methyl-AA (7b) turned out to be a weak AMPA receptor agonist and a weak mixed NMDA/AMPA receptor antagonist, respectively.

Alzheimer's disease–like pathology has transient effects on the brain and blood metabolome

“…In fact the L-enantiomeric form exerts an agonist activity, while the D-enantiomeric form acts as an antagonist (Brauner-Osborne et al, 2000;Guldbrandt et al, 2002). Since NMDA has been implicated in both cell death and neuronal excitotoxicity in AD (Butterfield and Pocernich, 2003), clearer delineation of the relative abundance of the D-and L-enantiomers of α-aminoadipic acid, would be useful to allow better interpretation of how these might modulate neurotoxicity via NMDA receptors with respect to AD pathology.…”

Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects

“…Alpha-amino adipidic acid ( α -AAA) decreased from baseline to day 1 following ketamine treatment, while in placebo it increased to 230 min and then slightly declined ( p = 0.006). A decrease in circulating levels of α -AAA would be beneficial, as it is a known mGluR2 agonist (Guldbrandt et al 2002), which has been reported to be an astrocytic toxin that can induce depressive-like behavior (Domin et al 2014). However, as the circulating levels were near the limit of quantitation, these findings need to be replicated.…”

Efficient synthesis of novel glutamate homologues and investigation of their affinity and selectivity profile at ionotropic glutamate receptors

“…[b] Data from ref. 22 Three out of the four tested compounds bound to NMDA receptor, with (R)-8 having the best affinity (Ki = 14 μM). Interestingly, the Ki value of (R)-8 is almost identical to that of (R)-AA, our reference NMDA antagonist.…”